Our Approach
Navigating the 340B Landscape
The 340B Drug Pricing Program can represent a significant financial opportunity for eligible hospitals, but qualification often hinges on complex Medicare DSH calculations, Medicaid eligibility reporting, operational decisions, and ongoing monitoring. TPR helps hospitals identify, evaluate, and implement defensible strategies that strengthen 340B qualification, maximize program value, and reduce future compliance risk.
Our team combines deep expertise in Medicare DSH reimbursement, patient-level data analytics, operational strategy, and regulatory guidance to help organizations uncover opportunities that may otherwise be missed. We deliver actionable recommendations, audit-ready documentation, and ongoing monitoring to support both immediate results and long-term sustainability.
Based on decades of Medicare reimbursement experience, TPR's approach balances financial optimization with compliance, ensuring organizations can confidently pursue 340B opportunities while maintaining alignment with CMS and HRSA requirements.

How will our services help you?
Key Benefits

Strengthen and Preserve 340B Eligibility
We identify opportunities to improve Medicare DSH performance through detailed evaluation of Medicaid eligible days, SSI ratios, inpatient day classifications, excluded-unit considerations, and operational drivers that impact qualification thresholds.

Maximize Financial Value Through Data-Driven Analysis
Our proprietary analytics and reimbursement expertise help quantify potential 340B savings, identify overlooked opportunities, and prioritize initiatives that can generate meaningful and sustainable financial results.

Maintain Audit-Ready Compliance
All recommendations are developed with an emphasis on regulatory transparency, documentation, and audit defensibility. We help organizations establish monitoring processes and governance structures that support long-term program success.


